Andrea Murphy is an attractive, youthful 52-year-old who says her life has been saved by an expensive "miracle" drug. She and seven other sufferers of PNH, an extremely rare blood and immune system disorder, are pleading with the government to fund that drug, Soliris, at a cost of $500,000 per person - a total $4 million a year for the rest of their lives.
PNH strikes in the prime of life, and can be a death sentence. Sufferers endure abdominal pain, shortness of breath and debilitating fatigue, culminating in blood clots and eventual organ failure. It's miserable, and none of us would wish it on our worst enemies.
The drug Soliris can prevent or reduce complications, and prolong the lives of those with the disorder. It is also, according to Forbes, the world's most expensive drug. And therein lies the conundrum.
Should the government heed the televised pleas of PNH sufferers like Murphy, who says it's a "crime" for drug-buying agency Pharmac to deny terminally ill people the treatment? Or should the government, perhaps, continue to fund the insertion of inexpensive plastic grommets in the ears of thousands of pre-schoolers who suffer glue ear?
These are the sorts of decisions Pharmac and the National Health Committee must make every month, under pressure from heart-tugging public relations campaigns.